GSK5460025 / GSK - LARVOL DELTA

First-in-human, phase 1/2 study of GSK5460025 in adults with advanced mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) solid tumors (ESMO-GI 2026) - No abstract available

Clinical • dMMR • First-in-human • Metastases • Mismatch repair • MSI-H • P1/2 data • Gastrointestinal Cancer • Oncology • Solid Tumor • MSI

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=47 | Recruiting | Sponsor: GlaxoSmithKline | N=27 ➔ 47

dMMR • Enrollment change • Mismatch repair • MSI-H • Trial initiation date • Colorectal Cancer • Endometrial Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: GlaxoSmithKline

dMMR • Mismatch repair • MSI-H • New P1/2 trial • Colorectal Cancer • Endometrial Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

224035: Phase 1/2 study to investigate the safety and preliminary efficacy of GSK5460025 alone or in combination with other anti-cancer agents in dMMR/MSI-H solid tumors (clinicaltrialsregister.eu) - P1/2 | N=22 | Not yet recruiting | Sponsor: Glaxosmithkline Research & Development Limited

dMMR • Mismatch repair • MSI-H • New P1/2 trial • Colorectal Cancer • Endometrial Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=47 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

dMMR • Enrollment open • Mismatch repair • MSI-H • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=47 | Not yet recruiting | Sponsor: GlaxoSmithKline

dMMR • Mismatch repair • MSI-H • New P1/2 trial • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor